Differential regulation of neurotoxin in HIV clades: Role of cocaine and methamphetamine

Current HIV Research

Volumn 10, Issue 5, 2012, Pages 429-434

  Nair, Madhavan P N ^a   Samikkannu, Thangavel ^a  

^a FLORIDA INTERNATIONAL UNIVERSITY   (United States)

Author keywords

Cocaine; Dementia and neurocognitive; HIV 1 clade B and C; Methamphatamine

Indexed keywords

ARACHIDONIC ACID; COCAINE; CYCLOOXYGENASE 2; GLUTAMIC ACID; GLYCOPROTEIN GP 120; INDOLEAMINE 2,3 DIOXYGENASE; METHAMPHETAMINE; N METHYL DEXTRO ASPARTIC ACID RECEPTOR; NEUROTOXIN; PHOSPHOLIPASE A2; PROSTAGLANDIN E2; QUINOLINIC ACID; THROMBOXANE A2; TRANSACTIVATOR PROTEIN;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ASTROCYTE; CENTRAL NERVOUS SYSTEM FUNCTION; CLADISTICS; COCAINE DEPENDENCE; COGNITIVE DEFECT; DENDRITIC CELL; EXCITOTOXICITY; GENE EXPRESSION; HIV 1 ASSOCIATED NEUROCOGNITIVE DISORDER; HIV ASSOCIATED DEMENTIA; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; HUMAN IMMUNODEFICIENCY VIRUS PREVALENCE; METHAMPHETAMINE DEPENDENCE; NEUROPATHOLOGY; NONHUMAN; OXIDATIVE STRESS; REVIEW; VIRUS PATHOGENESIS; VIRUS REPLICATION;

ACQUIRED IMMUNODEFICIENCY SYNDROME; AIDS DEMENTIA COMPLEX; ARACHIDONIC ACID; CENTRAL NERVOUS SYSTEM STIMULANTS; COCAINE; CYCLOOXYGENASE 2; DISEASE PROGRESSION; FEMALE; HIV ENVELOPE PROTEIN GP120; HIV-1; HUMANS; MALE; METHAMPHETAMINE; QUINOLINIC ACID; SUBSTANCE-RELATED DISORDERS; TAT GENE PRODUCTS, HUMAN IMMUNODEFICIENCY VIRUS; UP-REGULATION; VIRUS REPLICATION;

EID: 84866311793     PISSN: 1570162X     EISSN: 18734251     Source Type: Journal    
DOI: 10.2174/157016212802138742     Document Type: Review

References (71)

1. Goodkin K, Aronow A, Baldwin G, et al. HIV-1 associated neurocognitive disorders in the HAART era. In: The Spectrum of Neuro-AIDS Disorders. Washington DC: ASM Press; 2008.
2. Ances BM, Ellis RJ. Dementia and neurocognitive disorders due to HIV-1 infection. Semin Neurol 2007; 27: 86-92.
3. Navia BA. Clinical and biologic features of the AIDS dementia complex. Neuroimaging Clin N Am 1997; 7: 581-592.
4. Simon SL, Domier CP, Sim T, et al. Cognitive performance of current methamphetamine and cocaine abusers. J Addict Dis 2002; 21: 61-74.
5. Nardacci R, Antinori A, Kroemer G, et al. Cell death mechanisms in HIV-associated dementia: the involvement of syncytia. Cell Death Differ 2005; 12 Suppl 1: 855-858.
6. Brabers NA, Nottet HS. Role of the pro-inflammatory cytokines TNF-alpha and IL-1beta in HIV-associated dementia. Eur J Clin Invest 2006; 36: 447-458.
7. Nottet SLM, Jett M, Flanagan CR, Zhai et al. A regulatory role for astrocytes in HIV-1 encephalitis: an overexpression of eicosanoids, platelet-activating factor, and tumor necrosis factor-by activated HIV-1-infected monocytes is attenuated by primary human astrocytes. J Immunol 1996; 154: 3567-3581.
8. Holden CP, Nath A, Haughey NJ, et al. Involvement of Na+/H+ exchangers, Ca2+ channels, and excitatory amino acid receptors in intracellular Ca2+ responses to HIV-1 gp120 in cultured human fetal brain cells. Neuroscience 1999; 91: 1369-1378.
9. Heyes MP, Saito K, Lackner A, et al. Sources of the neurotoxin quinolinic acid in the brain of HIV-1-infected patients and retrovirus-infected macaques. FASEB J 1998; 12: 881-896.
10. Genis P, Jett M, Bernton EW, et al. Cytokines and arachidonic metabolites produced during human immunodeficiency virus (HIV)-infected macrophage-astroglia interactions: implications for the neuropathogenesis of HIV disease. J Exp Med 1992; 176: 1703-1718.
11. Griffin DE, Wesselingh SL, McArthur JC. Elevated central nervous system prostaglandins in human immunodeficiency virusassociated dementia. Ann Neurol 1994; 35: 592-597.
12. Heyes MP, Brew BJ, Martin A, et al. Quinolinic acid in cerebrospinal fluid and serum in HIV-1 infection: relationship to clinical and neurological status. Ann Neurol 1991; 29: 202-209.
13. Nokta MA, Hassan MI, Loesch KA, et al. HIV-induced TNFregulates arachidonic acid and PGE2 release from HIVinfected mononuclear phagocytes. Virology 1995; 208: 590-600.
14. Ross BM, Moszczynska A, Peretti FJ, et al. Decreased activity of brain phospholipid metabolic enzymes in human users of cocaine and methamphetamine. Drug Alcohol Depend 2002; 67: 73-79.
15. Samikkannu T, Saiyed ZM, Rao KV, et al. Differential Regulation of Indoleamine-2, 3-Dioxygenase (IDO) by HIV-1 Clade B and C Tat Protein. AIDS Res and Hum Retrovirus 2009; 25: 329-335.
16. Samikkannu T, Rao KV, Gandhi N, et al. Human immunodeficiency virus type 1 clade B and C Tat differentially induce indoleamine 2, 3-dioxygenase and serotonin in immature dendritic cells: Implications for neuroAIDS. J Neurovirol 2010; 16: 255-263.
17. Samikkannu T, Agudelo M, Gandhi N, et al. Human immunodeficiency virus type 1 clade B and C gp120 differentially induce neurotoxin arachidonic acid in human astrocytes: implications for neuroAIDS. J Neurovirol 2011; 17: 230-238.
18. Anggadiredja K, Nakamichi M, Hiranita T, et al. Endocannabinoid system modulates relapse to methamphetamine seeking: possible mediation by the arachidonic acid cascade, Neuropsychopharmacology 2004; 29: 1470-1478
19. Buydens-Branchey L, Branchey M, McMakin DL, et al. Polyunsaturated fatty acid status and relapse vulnerability in cocaine addicts. Psychiatry Res 2003; 120: 29-35.
20. UNAIDS/WHO. AIDS epidemic update: November 2009. UNAIDS, UNAIDS/09.36E. JC1700E. ISBN 9789291738328.
21. Robertson D, Anderson J, Bradac J, et al. A reference guide to HIV-1 classification. Los Alamos National Laboratory, Los Alamos, N.Mex 2000.
22. Robertson DL, Anderson JP, Bradac JA. HIV-1 nomenclature proposal. Science 2000; 288: 55-56.
23. Osmanov S, Pattou C, Walker N, et al. Estimated global distribution and regional spread of HIV-1 genetic subtypes in the year 2000. J Acquir Immune Defic Syndr 2000; 29: 184-190.
24. Weniger BG, Takebe Y, Ou CY, et al. The molecular epidemiology of HIV in Asia. AIDS 1994; 8 Suppl 2: S13-S28.
25. Janssens W, Buve A, Nkengasong JN. The puzzle of HIV-1 subtypes in Africa. AIDS 1997; 11: 705-712.
26. Piot P, Bartos M, Ghys PD, et al. The global impact of HIV/AIDS. Nature 2001; 410: 968-973.
27. Rambaut A, Robertson DL, Pybus OG, et al. Human immunodeficiency virus. Phylogeny and the origin of HIV-1. Nature 2001; 410: 1047-1048.
28. Kaleebu P, Ross A, Morgan D, et al. Relationship between HIV-1 Env subtypes A and D and disease progression in a rural Ugandan cohort. AIDS 2001; 15: 293-299.
29. Sanders RW, de Jong EC, Baldwin CE, et al. Differential transmission of human immunodeficiency virus type 1 by distinct subsets of effector dendritic cells. J Virol 2002; 76: 7812-7821.
30. Mishra M, Vetrivel S, Siddappa NB, et al. Clade-specific differences in neurotoxicity of human immunodeficiency virus-1 B and C Tat of human neurons: significance of dicysteine C30C31 motif. Ann Neurol 2008; 63: 366-376.
31. Campbell GR, Watkins JD, Singh KK, et al. Human immunodeficiency virus type 1 subtype C Tat fails to induce intracellular calcium flux and induces reduced tumor necrosis factor production from monocytes. J Virol 2007; 81: 5919-5928.
32. Satishchandra P, Nalini A, Gourie-Devi M, et al. Profile of neurologic disorders associated with HIV/AIDS from Bangalore, south India (1989-96). Indian J Med Res 2000; 111: 14-23.
33. Ranga, U, Shankarappa R, Siddappa NB, et al. Tat protein of human immunodeficiency virus type 1 subtype C strains is a defective chemokine. J Virol 2004; 78: 2586-2590.
34. Rizzuto CD, Wyatt R, Hernandez-Ramos N, et al. A conserved HIV gp120 glycoprotein structure involved in chemokine receptor binding. Science 1998; 280: 1949-1953.
35. Pattarini R, Pittaluga A, Raiteri M. The human immunodeficiency virus-1 envelope protein gp120 binds through its V3 sequence to the glycine site of N-methyl-D-aspartate receptors mediating noradrenaline release in the hippocampus. Neuroscience 1998; 87:147-157.
36. Yang Z, Nelson R. Estimating synonymous and nonsynonymous substitution rates under realistic evolutionary models. Mol. Biol Evol 2000; 17: 32-43.
37. Gnanakaran S, Lang D, Daniels M, et al. Clade-specific differences between human immunodeficiency virus type 1 clades B and C: diversity and correlations in C3-V4 regions of gp120. J Virol 2007; 81: 4886-4891.
38. Rao VR, Sas AR, Eugenin EA, et al. HIV-1 clade-specific differences in the induction of neuropathogenesis. J Neurosci 2008; 28: 10010-10016.
39. Nath A. Human immunodeficiency virus (HIV) proteins in neuropathogenesis of HIV dementia. J Infect Dis 2002; 186 Suppl 2: S193-S198.
40. Gonzalez-Scarano F, Baltuch G. Microglia as mediators of inflammatory and degenerative diseases. Annu Rev Neurosci 1999; 22: 219-240.
41. Zalenskaya IA, Cerocchi OG, Joseph T, et al. Increased COX-2 expression in human vaginal epithelial cells exposed to nonoxynol-9, a vaginal contraceptive microbicide that failed to protect women from HIV-1 infection. Am J Reprod Immunol 2011; 65: 569-577.
42. Koutsilieri E, ter Meulen V, Riederer P. Neurotransmission in HIV associated dementia: a short review. J Neural Transm 2001; 108: 767-775.
43. Thomas DM, Kuhn DM. Cyclooxygenase-2 is an obligatory factor in methamphetamine-induced neurotoxicity. J Pharmacol Exp Ther 2005; 313: 870-876.
44. Ingram SL, Amara SG. Arachidonic acid stimulates a novel cocaine-sensitive cation conductance associated with the human dopamine transporter. J Neurosci 2000; 20: 550-557.
45. Heyes MP, Ellis RJ, Ryan L, et al. HIV Neurobehavioral Research Center. Elevated cerebrospinal fluid quinolinic acid levels are associated with region-specific cerebral volume loss in HIV infection. Brain 2001; 124: 1033-1042.
46. Ensoli B, Bellino S, Tripiciano A, et al., Longo O, Therapeutic immunization with HIV-1 Tat reduces immune activation and loss of regulatory T-cells and improves immune function in subjects on HAART. PLoS One 2010; 5: e13540.
47. Gray F, Adle-Biassette H, Chrétien F, et al. Neuropathology and neurodegeneration in human immunodeficiency virus infection. Pathogenesis of HIV-induced lesions of the brain, correlations with HIV-associated disorders and modifications according to treatments. Clin Neuropathol 2001; 20: 146-155.
48. Haughey NJ, Mattson MP. Calcium dysregulation and neuronal apoptosis by the HIV-1 proteins Tat and gp120. J Acquir Immune Defic Syndr 2002; 31: S55-S61.
49. Marchiò S, Alfano M, Primo L, et al. Cell surface-associated Tat modulates HIV-1 infection and spreading through a specific interaction with gp120 viral envelope protein. Blood 2005; 105: 2802-2811.
50. Galicia O, Sanchez-Alavez M, Mendez Diaz M, et al. HIV glycoprotein 120: possible etiological agent of AIDS-associated dementia. Rev Invest Clin 2002; 54: 437-452.
51. Nath, A. Human immunodeficiency virus (HIV) proteins in neuropathogenesis of HIV dementia. J Infect Dis 2002; 186 Suppl 2: S193-S198.
52. Maccarrone M, Navarra M, Corasaniti MT, et al. Cytotoxic effect of HIV-1 coat glycoprotein gp120 on human neuroblastoma CHP100 cells involves activation of the arachidonate cascade. Biochem J 1998; 333: 45-49.
53. Guillemin GJ, Smythe G, Takikawa O, et al. Expression of Indoleamine 2,3-Dioxygenase and production of quinolinic acid by human microglia, astrocytes, and neurons. Glia 2004; 49: 15-23.
54. Sardar AM Reynolds GP. Frontal cortex indoleamine-2,3-dioxygenase activity is increased in HIV-1-associated dementia. Neurosci Lett 1995; 187: 9-12.
55. Sei S, Saito K, Stewart SK, et al. Increased human immunodeficiency virus (HIV) type 1 DNA content and quinolinic acid concentration in brain tissues from patients with HIV encephalopathy. J Infect Dis 1995; 172: 638-647.
56. Valle M. Price RW. Nilsson A, et al. CSF quinolinic acid levels are determined by local HIV infection: Cross-sectional analysis and modelling of dynamics following antiretroviral therapy. Brain 2004; 127: 1047-1060.
57. Campbell GR. Watkins JD. Singh KK, et al. Human immunodeficiency virus type 1 subtype C Tat fails to induce intracellular calcium flux and induces reduced tumor necrosis factor production from monocytes. J Virol 2007; 81: 5919-5928
58. Phillis JW, Horrocks LA, Farooqui AA. Cyclooxygenases, lipoxygenases, and epoxygenases in CNS: their role and involvement in neurological disorders. Brain Res Rev 2006; 52: 201-243.
59. Dawson VL, Dawson TM, Uhl GR, et al. Human immunodeficiency virus type 1 coat protein neurotoxicity mediated by nitric oxide in primary cortical cultures. Proc Natl Acad Sci USA 1993; 90: 3256-3259.
60. Corasaniti MT, Bellizzib C, Russo R, et al. Caspase-1 inhibitors abolish deleterious enhancement of COX-2 expression induced by HIV-1 gp120 in human neuroblastoma cells. Toxicol Lett 2003; 139: 213-219.
61. Basselin M Ramadan E, Igarashi M, et al. Imaging upregulated brain arachidonic acid metabolism in HIV-1 transgenic rats. J Cereb Blood Flow Metab 2010; 31: 486-493.
62. Kita T, Shimada K, Mastunari Y, et al. Methamphetamine-induced striatal dopamine neurotoxicity and cyclooxygenase-2 protein expression in BALB/c mice. Neuropharmacology 2000; 39: 399-406.
63. Grassi B, Graghentini G, Campana A, et al. Spatial working memory in asymptomatic HIV-infected subjects. J Neuropsychiatry Clin Neurosci 1999; 11, 387-391.
64. Berger JR, Kumar M, Kumar A, et al. Cerebrospinal fluid dopamine in HIV-1 infection. AIDS 1999; 8: 67-71.
65. Substance Abuse and Mental Health Services Administration, Office of Applied Studies. Results from the 2008 National Survey on Drug Use and Health: National Findings. DHHS Pub. No. SMA 09-4443, Rockville, MD: SAMHSA, 2009.
66. UNODC, 2009 UNODC, World drug report, United Nations Office on Drugs and Crime, Vienna, Austria (2009) http://wwwunodcorg/documents/wdr/WDR_2009/webpdf.
67. Darke S, Kaye S, McKetin R, et al. Major physical and psychological harms of methamphetamine use. Drug Alcohol Rev 2008; 27: 253-262.
68. Reiner BC, Keblesh JP, Xiong H. Methamphetamine abuse. HIV infection and neurotoxicity. Int J Physiol Pathophysiol Pharmacol 2009; 1: 162-179.
69. Sanders RW, de Jong EC, Baldwin CE, et al. Differential transmission of human immunodeficiency virus type 1 by distinct subsets of effector dendritic cells. J Virol 2002; 76: 7812-7821.
70. Gandhi N, Saiyed Z, Thangavel S, et al. Differential effects of HIV type 1 clade B and clade C Tat protein on expression of proinflammatory and antiinflammatory cytokines by primary monocytes. AIDS Res Hum Retroviruses 2009; 25: 691-699.
71. Rao VR, Sas AR, Eugenin EA, et al. HIV-1 clade-specific differences in the induction of neuropathogenesis. J Neurosci 2008; 28: 10010-100016.